BenzingaAugust 13, 2026 at 5:32 AM NY22 days ago

Wells Fargo Maintains Overweight on Definium Therapeutics, Raises Price Target to $72

Wells Fargo analyst Benjamin Burnett maintains Definium Therapeutics (NASDAQ:DFTX) with a Overweight and raises the price target from $68 to $72.

Read the Full Story at the Source

The summary here comes from the news provider; the rest of the article lives on the publisher's site — Benzinga

Companies in This Story